NovoCure Ltd. (NASDAQ:NVCR) fell 2.4% during trading on Thursday . The company traded as low as $11.61 and last traded at $11.67, with a volume of 245,383 shares traded. The stock had previously closed at $11.96.

A number of brokerages have recently commented on NVCR. Zacks Investment Research cut shares of NovoCure from a “hold” rating to a “sell” rating in a research note on Friday, May 13th. Wedbush reiterated an “outperform” rating and set a $30.00 target price on shares of NovoCure in a research report on Tuesday, May 10th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $28.57.

The stock’s market cap is $977.88 million. The firm’s 50-day moving average price is $11.42 and its 200 day moving average price is $13.49.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings data on Monday, May 9th. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.09. The business earned $13.10 million during the quarter, compared to the consensus estimate of $23.65 million. Equities research analysts forecast that NovoCure Ltd. will post ($1.38) earnings per share for the current fiscal year.

In other NovoCure news, COO Michael J. Ambrogi sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $12.24, for a total value of $244,800.00. Following the completion of the sale, the chief operating officer now owns 324,084 shares in the company, valued at $3,966,788.16. The sale was disclosed in a document filed with the SEC, which is available through this link.

A number of large investors have recently modified their holdings of the stock. Hartline Investment Corp purchased a new stake in shares of NovoCure during the fourth quarter worth $1,143,000. Century Capital Management LLC purchased a new stake in shares of NovoCure during the fourth quarter worth $2,970,000. Finally, Morgan Stanley purchased a new stake in shares of NovoCure during the fourth quarter worth $9,619,000.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.